Image 1 of 3
Image 2 of 3
Image 3 of 3
Triple Agonist GLP-3 30mg Analytical Research Material
30 mg
Triple-receptor agonist research material for metabolic and receptor-signaling investigation
Retatrutide 30 mg is an investigational research peptide studied for activity across three distinct receptor systems: the glucose-dependent insulinotropic polypeptide receptor (GIPR), glucagon-like peptide-1 receptor (GLP-1R), and glucagon receptor (GCGR).
Because retatrutide combines GIP, GLP-1, and glucagon receptor agonism within a single molecular structure, it has become a significant subject of research involving multi-receptor agonism, metabolic signaling, incretin pathways, receptor pharmacology, and pathway interaction.
Its triple-agonist architecture distinguishes retatrutide from research compounds designed around single- or dual-receptor mechanisms.
Each vial contains:
Retatrutide — 30 mg
Total peptide content — 30 mg
What is Retatrutide?
Retatrutide is a synthetic peptide-based triple receptor agonist investigated for coordinated signaling across GIPR, GLP-1R, and GCGR pathways.
GLP-1 and GIP belong to the broader incretin signaling system, while the glucagon receptor participates in a separate but closely connected network of metabolic and endocrine signaling.
Combining activity across all three receptor systems allows researchers to investigate how simultaneous receptor activation differs from targeting an individual pathway in isolation.
Retatrutide research commonly examines:
GLP-1 receptor signaling
GIP receptor signaling
Glucagon receptor signaling
Triple-receptor agonism
Multi-agonist peptide pharmacology
Incretin signaling pathways
Metabolic pathway signaling
Receptor selectivity and potency
Downstream intracellular signaling
Receptor pathway interaction and crosstalk
Why is Retatrutide researched?
One of the defining scientific characteristics of retatrutide is its ability to provide researchers with one molecular platform capable of activating three separate receptor pathways.
This makes it useful for studying how simultaneous GIP, GLP-1, and glucagon receptor signaling influences downstream cellular and metabolic pathways compared with isolated receptor activation.
Researchers can examine the relationship between these receptor systems, their relative signaling activity, and the way multiple pathways interact when activated by the same compound.
The triple-agonist design has therefore made retatrutide relevant to research involving:
metabolic signaling, incretin biology, endocrine communication, energy-regulation pathways, receptor pharmacology, and multi-receptor peptide design.
In simple terms, the scientific interest in retatrutide comes from researchers being able to examine three interconnected receptor systems through a single research compound.
What makes Retatrutide different?
Many peptide research compounds are designed around one primary receptor target.
Others combine two receptor activities.
Retatrutide is distinguished by its triple-receptor agonist architecture:
GIPR — GIP receptor
Studied in incretin biology, metabolic signaling, and receptor pharmacology.
GLP-1R — GLP-1 receptor
Extensively investigated in glucose-dependent signaling, endocrine communication, and metabolic pathway research.
GCGR — Glucagon receptor
Studied in hepatic signaling, substrate metabolism, endocrine signaling, and energy-regulation pathways.
The combined activity of these three receptor systems makes retatrutide particularly relevant to multi-agonist research and comparative receptor pharmacology.
Three receptor targets. One research compound. A distinctly different signaling profile.
What makes the TPG standard different?
We don’t rely on supplier paperwork alone.
Every TPG batch is built around independent analytical verification, lot-level traceability, and accessible testing documentation.
Where applicable to the analytical methods performed, independent laboratory testing evaluates whether the tested material matches its stated identity, quantity, and purity specifications.
Retatrutide — 30 mg
✓ Batch-specific identification
✓ Quantitative content analysis
✓ Chromatographic purity analysis where performed
✓ Independent third-party laboratory testing
✓ Lot-specific documentation
✓ Certificate of Analysis availability
✓ Cold stored and carefully shipped
The Peptide Group Standard
Supplier documentation tells you what a material is claimed to contain.
Independent analytical testing determines whether the tested sample matches those stated specifications.
That distinction is central to the TPG standard.
We focus on identifiable lots, independent analytical data, and documentation researchers can review rather than relying solely on manufacturer or supplier claims.
Our standard is straightforward:
Identity. Quantity. Purity. Traceability.
Clearly identified material backed by analytical documentation.
Research first. Receipts included.
Product Information
Retatrutide 30 mg is supplied as a single vial of analytical research material.
Lot-specific documentation and Certificate of Analysis information may be provided for applicable batches to support laboratory recordkeeping, material identification, analytical review, and batch traceability.
Specifications
Compound: Retatrutide
Content: 30 mg per vial
Compound class: Triple-receptor agonist research peptide
Primary receptor targets: GIPR, GLP-1R, GCGR
Primary research areas: Multi-receptor agonism, incretin signaling, metabolic signaling, receptor pharmacology
Analytical research material
Batch-specific identification
Independent third-party analytical testing
Certificate of Analysis where applicable
Lot-level traceability
Cold stored and carefully shipped
Research Use Notice
For analytical and laboratory research purposes only.
Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.
Manufacturer and supplier information may be redacted from publicly displayed certificates to protect proprietary sourcing information and prevent unauthorized duplication or reuse. Analytical results, purity data, tested content, and reported quantities are not altered by these redactions.
30 mg
Triple-receptor agonist research material for metabolic and receptor-signaling investigation
Retatrutide 30 mg is an investigational research peptide studied for activity across three distinct receptor systems: the glucose-dependent insulinotropic polypeptide receptor (GIPR), glucagon-like peptide-1 receptor (GLP-1R), and glucagon receptor (GCGR).
Because retatrutide combines GIP, GLP-1, and glucagon receptor agonism within a single molecular structure, it has become a significant subject of research involving multi-receptor agonism, metabolic signaling, incretin pathways, receptor pharmacology, and pathway interaction.
Its triple-agonist architecture distinguishes retatrutide from research compounds designed around single- or dual-receptor mechanisms.
Each vial contains:
Retatrutide — 30 mg
Total peptide content — 30 mg
What is Retatrutide?
Retatrutide is a synthetic peptide-based triple receptor agonist investigated for coordinated signaling across GIPR, GLP-1R, and GCGR pathways.
GLP-1 and GIP belong to the broader incretin signaling system, while the glucagon receptor participates in a separate but closely connected network of metabolic and endocrine signaling.
Combining activity across all three receptor systems allows researchers to investigate how simultaneous receptor activation differs from targeting an individual pathway in isolation.
Retatrutide research commonly examines:
GLP-1 receptor signaling
GIP receptor signaling
Glucagon receptor signaling
Triple-receptor agonism
Multi-agonist peptide pharmacology
Incretin signaling pathways
Metabolic pathway signaling
Receptor selectivity and potency
Downstream intracellular signaling
Receptor pathway interaction and crosstalk
Why is Retatrutide researched?
One of the defining scientific characteristics of retatrutide is its ability to provide researchers with one molecular platform capable of activating three separate receptor pathways.
This makes it useful for studying how simultaneous GIP, GLP-1, and glucagon receptor signaling influences downstream cellular and metabolic pathways compared with isolated receptor activation.
Researchers can examine the relationship between these receptor systems, their relative signaling activity, and the way multiple pathways interact when activated by the same compound.
The triple-agonist design has therefore made retatrutide relevant to research involving:
metabolic signaling, incretin biology, endocrine communication, energy-regulation pathways, receptor pharmacology, and multi-receptor peptide design.
In simple terms, the scientific interest in retatrutide comes from researchers being able to examine three interconnected receptor systems through a single research compound.
What makes Retatrutide different?
Many peptide research compounds are designed around one primary receptor target.
Others combine two receptor activities.
Retatrutide is distinguished by its triple-receptor agonist architecture:
GIPR — GIP receptor
Studied in incretin biology, metabolic signaling, and receptor pharmacology.
GLP-1R — GLP-1 receptor
Extensively investigated in glucose-dependent signaling, endocrine communication, and metabolic pathway research.
GCGR — Glucagon receptor
Studied in hepatic signaling, substrate metabolism, endocrine signaling, and energy-regulation pathways.
The combined activity of these three receptor systems makes retatrutide particularly relevant to multi-agonist research and comparative receptor pharmacology.
Three receptor targets. One research compound. A distinctly different signaling profile.
What makes the TPG standard different?
We don’t rely on supplier paperwork alone.
Every TPG batch is built around independent analytical verification, lot-level traceability, and accessible testing documentation.
Where applicable to the analytical methods performed, independent laboratory testing evaluates whether the tested material matches its stated identity, quantity, and purity specifications.
Retatrutide — 30 mg
✓ Batch-specific identification
✓ Quantitative content analysis
✓ Chromatographic purity analysis where performed
✓ Independent third-party laboratory testing
✓ Lot-specific documentation
✓ Certificate of Analysis availability
✓ Cold stored and carefully shipped
The Peptide Group Standard
Supplier documentation tells you what a material is claimed to contain.
Independent analytical testing determines whether the tested sample matches those stated specifications.
That distinction is central to the TPG standard.
We focus on identifiable lots, independent analytical data, and documentation researchers can review rather than relying solely on manufacturer or supplier claims.
Our standard is straightforward:
Identity. Quantity. Purity. Traceability.
Clearly identified material backed by analytical documentation.
Research first. Receipts included.
Product Information
Retatrutide 30 mg is supplied as a single vial of analytical research material.
Lot-specific documentation and Certificate of Analysis information may be provided for applicable batches to support laboratory recordkeeping, material identification, analytical review, and batch traceability.
Specifications
Compound: Retatrutide
Content: 30 mg per vial
Compound class: Triple-receptor agonist research peptide
Primary receptor targets: GIPR, GLP-1R, GCGR
Primary research areas: Multi-receptor agonism, incretin signaling, metabolic signaling, receptor pharmacology
Analytical research material
Batch-specific identification
Independent third-party analytical testing
Certificate of Analysis where applicable
Lot-level traceability
Cold stored and carefully shipped
Research Use Notice
For analytical and laboratory research purposes only.
Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.
Manufacturer and supplier information may be redacted from publicly displayed certificates to protect proprietary sourcing information and prevent unauthorized duplication or reuse. Analytical results, purity data, tested content, and reported quantities are not altered by these redactions.